Fosamprenavir (Telzir, Lexiva)

Fosamprenavir (Telzir) is an anti-HIV drug that reduces the amount of virus in the body. Anti-HIV drugs such as fosamprenavir slow down or prevent damage to the immune system and reduce the risk of developing AIDS-related illnesses.

Fosamprenavir is a protease inhibitor. Protease (or proteinase) is the protein or enzyme that HIV uses to break up large viral proteins so new HIV particles can be made. For more information about how protease inhibitors work, see Protease inhibitors.

Fosamprenavir was approved in the European Union in July 2004 under the brand name Telzir for use in combination with low-dose ritonavir (Norvir) in HIV-positive adults.

In the United States, fosamprenavir was approved for use with or without ritonavir boosting in October 2003 and is marketed under the trade name Lexiva.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.